- Home
- ACIU vs STIM Comparison
ACIU vs STIM Comparison
Compare ACIU & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- STIM
- Stock Information
- Founded
- ACIU 2003
- STIM 2003
- Country
- ACIU Switzerland
- STIM United States
- Employees
- ACIU N/A
- STIM N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- STIM Medical/Dental Instruments
- Sector
- ACIU Health Care
- STIM Health Care
- Exchange
- ACIU Nasdaq
- STIM Nasdaq
- Market Cap
- ACIU 173.7M
- STIM 232.3M
- IPO Year
- ACIU 2016
- STIM 2018
- Fundamental
- Price
- ACIU $1.68
- STIM $4.43
- Analyst Decision
- ACIU Strong Buy
- STIM Buy
- Analyst Count
- ACIU 2
- STIM 4
- Target Price
- ACIU $10.00
- STIM $6.00
- AVG Volume (30 Days)
- ACIU 133.4K
- STIM 792.7K
- Earning Date
- ACIU 04-30-2025
- STIM 05-06-2025
- Dividend Yield
- ACIU N/A
- STIM N/A
- EPS Growth
- ACIU N/A
- STIM N/A
- EPS
- ACIU N/A
- STIM N/A
- Revenue
- ACIU $32,014,254.00
- STIM $89,448,000.00
- Revenue This Year
- ACIU N/A
- STIM $102.36
- Revenue Next Year
- ACIU $676.94
- STIM $9.83
- P/E Ratio
- ACIU N/A
- STIM N/A
- Revenue Growth
- ACIU 91.20
- STIM 22.16
- 52 Week Low
- ACIU $1.43
- STIM $0.52
- 52 Week High
- ACIU $4.98
- STIM $5.92
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- STIM 54.83
- Support Level
- ACIU $1.55
- STIM $3.30
- Resistance Level
- ACIU $1.79
- STIM $4.82
- Average True Range (ATR)
- ACIU 0.10
- STIM 0.32
- MACD
- ACIU 0.03
- STIM 0.03
- Stochastic Oscillator
- ACIU 66.67
- STIM 74.59
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.